Clinical trials: BPH
Benign Prostatic Hyperplasia
The ProVerum First in Man PROVE Study
A clinical evaluation to assess the safety and performance of the ProVeeTM Urethral Expander System, designed to alleviate the symptoms of Benign Prostatic Hyperplasia (BPH).
- Trial name
- NCT03972371
- Testing
- The ProVee Urethral Expander System
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- ProVerum Medical
Calculi, Renal, Calculi, Urinary
Modified SOLTIVE Study
This is a study to collect procedural data during the use of the SOLTIVE™ Premium SuperPulsed Laser System in the treatment of bladder, ureteral, and kidney stones and BPH to inform the development of software algorithms.
- Conditions
- Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
- Trial name
- NCT07838077
- Testing
- SOLTIVE Premium SuperPulsed Laser System
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Olympus Corporation of the Americas
Neoplasms, Prostate, Benign Prostatic Hyperplasia
Economic Analyses of the REDUCE Trial
The objective of this project is to conduct a retrospective economic analysis of the use of dutasteride for the prevention of prostate cancer based on data from the REDUCE clinical trial.
- Conditions
- Neoplasms, Prostate, Benign Prostatic Hyperplasia, Cancer
- Trial name
- NCT01337258
- Testing
- Dutasteride
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Efficacy and Safety of MCS-2 in the Treatment of Lower Urinary Tract Symptoms
The hypothesis of the study is to examine whether MCS-2 is safe and effective in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
- Trial name
- MCS_LUTS (NCT01002664)
- Testing
- MCS-2
- Where
- Taiwan
- Volunteers
- 272 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
BPH, Nocturia
Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy
Benign prostate hypertrophy (BPH) and inflammation are common non-cancerous enlargement of the prostate, which result in urinary interference and incomplete drainage of the bladder.
- Conditions
- BPH, Nocturia, BPH With Urinary Obstruction, Prostatism
- Trial name
- SVF-BPN (NCT02961114)
- Testing
- Microcannula Harvest Adipose, Centricyte 1000, IV Sterile Normal Saline
- Where
- 2 sites in United States
- Sponsor
- Robert W. Alexander, MD, FICS
Benign Prostatic Hyperplasia
Evaluation of the ProstaPlant Prostate Stent Insertion in Ex Vivo Human Prostate
The purpose of this ex-vivo study is to evaluate the insertion procedure for the ProstaPlant implant in human prostates and the support that it supplies to the prostate.
- Trial name
- NCT00468026
- Testing
- ProstaPlant Stent
- Where
- Israel
- Sponsor
- ProstaPlant Urology System Ltd.
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Evaluation of the Safety, Tolerability, and Efficacy of the Omega System for the Treatment of LUTS Due to BPH
This is a prospective, two-stage, multi-center, pilot clinical study to evaluate the safety/tolerability/efficacy of the Omega System device.
- Trial name
- Omega (NCT05757687)
- Testing
- Omega device
- Where
- 5 sites in Georgia
- Volunteers
- 11 people
- Sponsor
- ProArc Medical
BPH (Benign Prostatic Hyperplasia), Lower Urinary Tract Symptoms (LUTS)
Safety and Effectiveness Study of the Zenflow Spring System
Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.
- Trial name
- BREEZE (NCT04987138)
- Testing
- Zenflow Spring System
- Where
- 7 sites in United States
- Volunteers
- 279 people
- Sponsor
- Zenflow, Inc.
Benign Prostate Hyperplasia
Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)
The primary objective of the post-marketing study is to collect safety and effectiveness data for 5 years on subjects treated with Prolieve®.
- Trial name
- NCT02021032
- Testing
- Prolieve
- Where
- 8 sites in United States
- Volunteers
- 250 people
- Sponsor
- Medifocus, Inc.
Benign Prostatic Hyperplasia (BPH)
Post-Market Study to Assess iTind Safety in Comparison to UroLift
The study objective is to evaluate the efficacy and safety of the iTind device compared to UroLift.
- Trial name
- MT-08 (NCT04757116)
- Testing
- iTind, UroLift
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 256 people
- Sponsor
- Olympus Corporation of the Americas
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)
Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia…
- Trial name
- NCT00743184
- Testing
- ozarelix
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Benign Prostatic Hyperplasia, Prostate Cancer
Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
Dutasteride is used in the treatment of benign prostate enlargement (BPH).It inhibits conversion of testosterone (T) into the more potent dihydrotestosterone (DHT) to stop prostate (and possibly prostate cancer) growth.
- Trial name
- NCT00375765
- Testing
- Dutasteride
- Where
- 2 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia
The primary objective of this study is to assess the safety and tolerance of transurethral photodynamic therapy (PDT) with QLT0074. Secondary objectives are: 1.
- Trial name
- NCT00077012
- Testing
- QLT0074, Photodynamic therapy
- Where
- 7 sites in United States, Canada
- Sponsor
- QLT Inc.
Benign Prostatic Hyperplasia (BPH)
Study to Assess the Efficacy of Medi-Tate iTind Device
The study will include an implantation of the iTind device and 4 follow up visits up to 12 months after the implantation.
- Trial name
- NCT02145208
- Testing
- TIND System
- Where
- 8 sites in Belgium, Italy and 3 more
- Volunteers
- 81 people
- Sponsor
- Medi-Tate Ltd.
Overactive Bladder
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
This study will assess the long-term safety of vibegron when dosed up to 52 weeks in men with overactive bladder (OAB) symptoms on pharmacological therapy for Benign Prostatic Hyperplasia (BPH) who previously completed treatment…
- Trial name
- NCT04103450
- Testing
- Vibegron
- Where
- 35 sites in United States, Poland
- Volunteers
- 276 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hyperplasia
A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as tadalafil in participants with benign prostatic hyperplasia who are being treated with an alpha1 blocker.
- Trial name
- NCT02431754
- Testing
- Tadalafil, Alpha1 Blocker
- Where
- 9 sites in Japan
- Volunteers
- 171 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State
This study will be an open-label, randomized, single dose, three way partial crossover study in healthy male subjects. The aim of the study is to evaluate bioequivalence of a fixed dose combination (FDC) capsule of dutasteride…
- Trial name
- NCT00537654
- Testing
- Treatment sequence A, Treatment sequence B, Treatment sequence C
- Where
- 2 sites in United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Phase 3 Study of Tadalafil Once-Daily in Asian Men With Benign Prostatic Hyperplasia (BPH)
This is a phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks in Asian men with signs and symptoms of benign…
- Trial name
- NCT01460342
- Testing
- Tadalafil
- Where
- 17 sites in Japan, South Korea
- Volunteers
- 610 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study of Tadalafil in Benign Prostatic Hyperplasia
The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH). The safety of tadalafil will also be studied.
- Trial name
- NCT01183650
- Testing
- Tadalafil
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company